4.5 Article

Genome-Wide Association Study of Prostate Cancer-Specific Survival

期刊

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 24, 期 11, 页码 1796-1800

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-15-0543

关键词

-

资金

  1. Swedish Cancer Society [2012/823]
  2. Swedish Research Council [2014/2269]
  3. Cancer Foundation Finland sr [140163] Funding Source: researchfish
  4. Cancer Research UK [17528, 16563, 19170, 13065, 16561, 16491, 15007, 14136] Funding Source: researchfish
  5. Cancer Research UK
  6. The Francis Crick Institute [10124] Funding Source: researchfish
  7. Medical Research Council [G1000143, G0401527] Funding Source: researchfish
  8. National Institute for Health Research [NF-SI-0512-10114, NF-SI-0509-10242] Funding Source: researchfish

向作者/读者索取更多资源

Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据